Median Technologies Shares Climb to €5.17, Targeting €5.50 Resistance
Median Technologies shares have significantly advanced in mid-afternoon trading to €5.17, a gain of 4.34% from the last close at €4.955. The small-cap company from the French Riviera, specializing in AI-assisted medical imaging, is performing in a rising Paris market, with the CAC 40 up by 0.32% during the session. Over the past twelve months, the stock now shows a performance increase of 123.8%.
Median Technologies Challenges €5.50 Resistance and Breaks Above Bollinger Bands
Median Technologies' stock is challenging its technical resistance identified at €5.50 after rebounding from the support level at €4.55. At €5.17, the price has broken above the upper Bollinger Band (upper limit at €5.14), indicating strong buying pressure during the session. The stock is trading above its three moving averages, with a 46.88% gap from the MM200 at €3.52, signaling that the medium-term momentum remains intact. The RSI at 53 remains neutral, allowing for technical leeway despite the Bollinger break. The stock has risen 5.83% over the week and has doubled in value over the year.
Record Order Book of €79.8 Million and FDA Approval Milestone for eyonis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
During the announcement of the annual results for 2025 (on April 23, 2026), the company had reduced its operational loss to €16.3 million from €22.5 million a year earlier, and raised its order book to a record level of €79.8 million as of March 31, 2026. Among the opportunities mentioned on this occasion were the anticipated FDA approval for eyonis LCS, its early lung cancer detection solution, and the partnership formed with Tempus to expand access to this technology in the American market. The management also highlighted two risk factors: the decline in Chinese demand and regulatory pressure on approvals. The crossing of the €5.50 mark will be the next technical milestone observable on the stock.
Related
SectorÉquipements et Services Médicaux›Équipements Médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1S2026
Key reported figures
Revenue: 11.8M€
Guidance from the release
Median a renforcé sa position grâce à l'augmentation de capital.
Performance solide avec un fort carnet de commandes.
Risks mentioned
Risques de fluctuations de demande dans l'industrie biopharmaceutique.
Réglementations changeantes pouvant impacter la commercialization.
Concurrence accrue sur le marché des dispositifs médicaux.
Opportunities identified
Lancement commercial d'eyonis® LCS aux États-Unis.
Partenariat stratégique avec Tempus AI en cours.
Croissance continue de l'activité iCRO avec des niveaux de carnet de commandes record.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
